No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
FGEN FibroGen
- 0.743
- -0.027-3.52%
Close Jul 2 16:00 ET
- 0.750
- +0.007+0.94%
Post 17:13 ET
73.91MMarket Cap-304P/E (TTM)
0.791High0.732Low3.59MVolume0.778Open0.770Pre Close2.74MTurnover3.96%Turnover RatioLossP/E (Static)99.48MShares2.93052wk High-0.32P/B67.32MFloat Cap0.33352wk Low--Dividend TTM90.61MShs Float68.550Historical High--Div YieldTTM7.69%Amplitude0.333Historical Low0.763Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | FibroGen Inc Files for Mixed Shelf of up to $300 Mln - SEC Filing
Goldman Sachs Maintains FibroGen(FGEN.US) With Sell Rating
Goldman Sachs analyst Paul Choi maintains $FibroGen(FGEN.US)$ with a sell rating.According to TipRanks data, the analyst has a success rate of 48.5% and a total average return of 5.1% over the past ye
Favourable Signals For FibroGen: Numerous Insiders Acquired Stock
FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Cancer on June 26, 2024
SAN FRANCISCO, June 18, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced it will host the second part of its virtual KOL investor event series on Wednesday, June 26, 2024 at 10:00 AM ET. To
FibroGen(FGEN.US) Officer Buys US$25,883.91 in Common Stock
$FibroGen(FGEN.US)$ Officer Adib Deyaa purchased 22,123 shares of common stock on Jun 12, 2024 at an average price of $1.17 for a total value of $25,883.91.Source: Announcement What is statement of ch
Pancreatic Cancer on the Rise: How Biotech Firms Are Developing Groundbreaking Treatments
After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovered that Generation X may ...
Comments
$FibroGen(FGEN.US$ Officer Adib Deyaa purchased 22,123 shares of common stock on Jun 12, 2024 at an average price of $1.17 for a total value of $25,883.91.
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors.
FibroGen, Inc. (NASDAQ:FGEN) recently announced a milestone in its oncology pipeline. The U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for FG-3165, a novel galectin-9 (Gal9) targeted monoc...
FibroGen, Inc. (NASDAQ:FGEN) recently announced a milestone in its oncology pipeline. The U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for FG-3165, a novel galectin-9 (Gal9) targeted monoc...
2
$FibroGen(FGEN.US$
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors
FibroGen (NASDAQ: FGEN) announced FDA clearance for its Investigational New Drug (IND) application for FG-3165, a monoclonal antibody targeting galectin-9 (Gal9) for treating solid tumors. FG-3165 has shown anti-tumor activity and improved survival in preclinical models and exhibited excellent tol...
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors
FibroGen (NASDAQ: FGEN) announced FDA clearance for its Investigational New Drug (IND) application for FG-3165, a monoclonal antibody targeting galectin-9 (Gal9) for treating solid tumors. FG-3165 has shown anti-tumor activity and improved survival in preclinical models and exhibited excellent tol...
3
$FibroGen(FGEN.US$
FibroGen Announces Clinical Trial Supply Agreement With Regeneron Pharmaceuticals to Evaluate Fibrogen’s Immuno-Oncology Assets, FG-3165 (Anti-Galectin 9) and FG-3175 (Anti-Ccr8), in Combination With Libtayo® in Upcoming Clinical Trials
FibroGen Announces Clinical Trial Supply Agreement With Regeneron Pharmaceuticals to Evaluate Fibrogen’s Immuno-Oncology Assets, FG-3165 (Anti-Galectin 9) and FG-3175 (Anti-Ccr8), in Combination With Libtayo® in Upcoming Clinical Trials
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg